All these in vitro results combined with the dimerization pattern in HER-2 positive human breast cancer tissues suggest that HRG1 expression is not a suitable predictive factor for HER-3 targeting agents, while the formation of HER-1:HER-4 heterodimer may represent a potential predictive factor for this class of agents. This evidence concerns the gene NRG1 and breast carcinoma.